Sign in

CIK 0001231457 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

GENELUX Corp

Sign in to watch
Ticker
GNLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
805-267-9889
Business address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$155,693
in 6 filings

Net −$155,693. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 71 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2024-03-14 Yu Yong VP, Clinical Trial Operations Grant or award +11,557 17,718
2024-03-14 Ryder Sean General Counsel Grant or award +9,270 22,778
2024-03-14 Jewett Caroline Head of Quality Grant or award +3,612 25,890
2024-02-19 Zindrick Thomas President and CEO Grant or award +8,320 22,971
2024-02-19 Zak Lourie S. Chief Financial Officer Grant or award +1,220 32,470
2024-02-19 Smalling Ralph Head of Regulatory Grant or award +616 13,931
2024-02-19 Cappello Joseph VP, Pharmaceutical Development Grant or award +3,661 9,396
2024-02-19 Yu Yong VP, Clinical Trial Operations Grant or award +3,661 6,161
2024-02-19 Ryder Sean General Counsel Grant or award +2,936 13,508
2024-02-19 Jewett Caroline Head of Quality Grant or award +1,143 22,278

Page 9 of 9 · 170 trades